Drug Classes

Antidepressants and Weight Change: An Evidence-Based Tool

Dent et al [1] conducted a systematic synthesis of the literature to rank the effect of psychotropic drugs on weight change. We summarize and reproduce some of their findings for antidepressant medications. Some key points include: Paroxetine and mirtazapine rank in the first two positions of drug-induced weight gain Tricyclic antidepressants and MAOIs are associated…

Read More

The Psychopharmacology of Bupropion: An Illustrated Overview

Author: Flavio Guzman, MD Bupropion is a norepinephrine dopamine reuptake inhibitor, or NDRI. It is approved as antidepressant as well as for smoking cessation. Some characteristic aspects of its side effects profile include a lack of sexual side effects, compared to other antidepressants and an increased risk of seizures. This presentation reviews the essential aspects…

Read More

Adverse Effects of SSRIs

Author: Flavio Guzman, MD The video below is a brief (length 2:30) overview on the adverse effects of SSRIs. Contents: General concepts Gastrointestinal side effects CNS adverse effects: Basal ganglia Mental effects Sexual dysfunction Download Video Transcript Hello, this is Dr. Flavio Guzman, I´m the editor of Psychopharmacology Institute. In this short video I’m going…

Read More

Ziprasidone Adverse Effects

Source: Drug labeling information submitted to the Food and Drug Administration (FDA), updated by the National Library of Medicine (NLM). Commonly observed adverse reactions (incidence ≥5% and at least twice the incidence for placebo) were: Schizophrenia: Somnolence, respiratory tract infection. Manic and Mixed Episodes Associated with Bipolar Disorder: Somnolence, extrapyramidal symptoms, dizziness, akathisia, abnormal vision,…

Read More

Ziprasidone (Geodon) Pharmacokinetics

Source: Drug labeling information submitted to the Food and Drug Administration (FDA), updated by the National Library of Medicine (NLM). Oral Pharmacokinetics Ziprasidone’s activity is primarily due to the parent drug. The multiple-dose pharmacokinetics of ziprasidone are dose-proportional within the proposed clinical dose range, and ziprasidone accumulation is predictable with multiple dosing. Elimination of ziprasidone…

Read More

Mechanism of Action and Pharmacodynamics of Ziprasidone

By: Flavio Guzman, MD Mechanism of Action The mechanism of action of ziprasidone, as with other drugs having efficacy in schizophrenia, is unknown. However, it has been proposed that this drug’s efficacy in schizophrenia is mediated through a combination of dopamine type 2 (D2) and serotonin type 2 (5HT2) antagonism. As with other drugs having…

Read More

Ziprasidone (Geodon) Indications: FDA-Approved Uses

Source: Drug labeling information submitted to the Food and Drug Administration (FDA), updated by the National Library of Medicine (NLM). Indications and Usage GEODON is an atypical antipsychotic. In choosing among treatments, prescribers should be aware of the capacity of GEODON to prolong the QT interval and may consider the use of other drugs first.…

Read More

Olanzapine Interactions

Source: Drug labeling information submitted to the Food and Drug Administration (FDA), updated by the National Library of Medicine (NLM). The risks of using olanzapine in combination with other drugs have not been extensively evaluated in systematic studies. Potential for Other Drugs to Affect Olanzapine Diazepam — The co-administration of diazepam with olanzapine potentiated the orthostatic…

Read More

Olanzapine Adverse Effects

Source: Drug labeling information submitted to the Food and Drug Administration (FDA), updated by the National Library of Medicine (NLM). Most common adverse reactions (≥5% and at least twice that for placebo) associated with: Oral Olanzapine Monotherapy: Schizophrenia (Adults) – postural hypotension, constipation, weight gain, dizziness, personality disorder, akathisia Schizophrenia (Adolescents) – sedation, weight increased, headache, increased…

Read More

Mechanism of Action and Pharmacodynamics of Olanzapine

By: Flavio Guzman, MD Olanzapine is a second-generation antipsychotic that acts as antagonist at 5HT2A and D2 receptors. Mechanism of Action The mechanism of action of olanzapine, as with other drugs having efficacy in schizophrenia, is unknown. However, it has been proposed that this drug’s efficacy in schizophrenia is mediated through a combination of dopamine…

Read More